“Our strategy of investing in future capacity will ensure our ability to provide quality service for this high level of customer need as our partners’ programmes progress,” said chief executive John Burt.
Showing 25 of 1607
The year has started well, but does the current valuation of the business reflect progress to date? Two leading City analysts think the stock has further to go.
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
The Sierra licence triggered an upfront payment to Sareum
We’ve had the final results from Holy Trinity of the UK pharma industry ... which is the one to back?
AstraZeneca said patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival.
Shire's results revealed net income had grown 75% to US$3.4bn as a result of the Baxalta takeover
A total of 32 patients will receive Acarovac MPL. The trial is expected to take 12 months from start to finish.
It has unveiled plans to raise as much as £12mln, which should transform the business.
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
GSK says the results of its phase three study of its HIV treatment may change our understanding of how the virus can be managed.
"the capital will provide the company with the opportunity to fund the development of a range of exciting new products for use in the rapidly emerging field of regenerative medicine,” said chief executive Jamal Rushdy.
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
CANCER-ID is backed by €14mln of funding and involves 38 companies and institutions from 13 countries across Europe.
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
The Skinny Tan firm said revenues jumped 125.5% to £3.187mln in the six months to December 31 driven by a successful penetration of the UK market.
The FTSE 100-listed firm posted trading profits of US$1.020bn for 2016, down 7% from 2015’s US$1.099bn, on revenue 1% higher at US$4.67bn.
Faron believes its drug, Traumakine, could revolutionise the intensive care treatment for patients with acute respiratory distress syndrome – a lung condition that currently has a high death rate.
The proceeds will be used to develop two highly promising cancer drug treatments.
Core earnings per share was 102.4p, at the top end of guidance for the year, but current year guidance was heavily caveated
MyLotus has been developed for women who have been trying to conceive for six months or more.
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
A technology transfer and licence agreement has been agreed with Selective Antibodies, a UK based diagnostics company
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
Mark Sumeray, Amryt’s chief medical officer, said: “These positive data results are encouraging and further reinforce our view that AP102 has the potential to improve outcomes for patients suffering from acromegal".